drugset / Trial / NCT04697290
CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.
Phase 0
Suspended
12 enrolled
Beijing Tsinghua Chang Gung Hospital
China Immunotech Pharmaceuticals Co.Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of CD19/CD20 Dual-CAR-T cells in patients with refractory or relapsed B-NHL.
Timeline
- Start
- 2022-03-10
- Primary completion
- 2023-03-10
- Completion
- 2023-06-10
Outcome
Outcome not reported
Stopped: “Plan adjustment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19/CD20 Dual-CAR-T cells | Cell therapy | 2e+06 cells/kg | Intravenous |
| Subject | CD19/CD20 Dual-CAR-T cells | Cell therapy | 6e+06 cells/kg | Intravenous |
| Subject | CD19/CD20 Dual-CAR-T cells | Cell therapy | 1e+07 cells/kg | Intravenous |
| Subject | CD19/CD20 Dual-CAR-T cells | Cell therapy | 3e+07 cells/kg | Intravenous |